Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer

Article Abstract:

Small cell lung cancer is more responsive to chemotherapy and radiotherapy than are other forms of lung cancer. Nevertheless, most patients still relapse, and cures are rare. After failure of initial therapy, death comes rapidly, occurring within seven to eight weeks following relapse. An attempt was made to evaluate the use of high-dose etoposide with cisplatin for the treatment of small cell lung cancer in 20 patients who had relapsed after initial treatment. Two patients died from infections following treatment. Of the remaining 18 patients, half achieved responses. The average survival time was 20.3 weeks, indicating a synergistic effect between the high-dose etoposide and cisplatin. The study also experimentally treated five patients with recombinant granulocyte colony-stimulating factor in an effort to reduce the period of white blood cell suppression which follows the chemotherapy. (It is during this period that potentially fatal infections are most likely to occur.) There was no evidence that the exogenous colony-stimulating factor reduced the white blood cell recovery time in these patients. (Consumer Summary produced by Reliance Medical Information, Inc.)

Health aspects, Chemotherapy, Combination, Combination chemotherapy, Cisplatin, Lung cancer, Small cell, Small cell lung cancer, Etoposide

---

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia

Article Abstract:

Interferon alfa-2b combined with cytarabine seems more beneficial than interferon alfa-2b alone in the treatment of chronic myelogenous leukemia. Researchers randomly assigned 360 leukemia patients to take both drugs and 361 to take interferon alfa-2b alone. Three years after treatment began, survival rates were 86% in the combination treatment group and 79% in the interferon alfa-2b group. Forty-one percent of the patients taking both drugs had responded within 1 year, compared to 24% of those taking interferon alfa-2b alone.

Interferon alpha, Chronic myeloid leukemia, Cytarabine

---

Similar abstracts:

• Abstracts: Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer
• Abstracts: Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. Thermo-chemo-radiotherapy of esophageal cancer: a preliminary report of 34 cases
• Abstracts: Expression of blood-group antigen A - a favorable prognostic factor in non-small-cell lung cancer. Flow cytometric analysis of the DNA content of non-small cell lung cancer: ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung
• Abstracts: Evaluation of the efficacy of Doppler flow velocity waveform analysis as a screening test in pregnancy. Middle cerebral artery blood flow in normal and growth-retarded fetuses
• Abstracts: Synovial fluid concentration of five different cytokines in rheumatic diseases. Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.